Evidence map›Paper›PMID 33354866›Full record

ArticleLiver international : official journal of the International Association for the Study of the Liver2021

Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis.

Daniela S Allende, Samer Gawrieh, Oscar W Cummings, Patricia Belt, Laura Wilson, Mark Van Natta, Cynthia A Behling, Danielle Carpenter, Ryan M Gill, David E Kleiner and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Liver international : official journal of the International Association for the Study of the Liver, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Science advances · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Dragon Fruit Peel (Antioxidants (Basel, Switzerland) · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Hepatocyte mARC1 promotes fatty liver disease.JHEP reports : innovation in hepatology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 1 country.

Daniela S AllendeDepartment of Pathology, Cleveland Clinic, Cleveland, OH, USA.
Samer GawriehDepartment of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Oscar W CummingsDepartment of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA.
Patricia BeltCenter for Clinical Trials, The Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA.
Laura WilsonCenter for Clinical Trials, The Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA.
Mark Van NattaCenter for Clinical Trials, The Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA.
Cynthia A BehlingDepartment of Pathology, Pacific Rim Pathology, San Diego, CA, USA.
Danielle CarpenterDepartment of Pathology, Saint Louis University, St Louis, MI, USA.
Ryan M GillDepartment of Pathology, University of California San Francisco, San Francisco, CA, USA.
David E KleinerLaboratory of Pathology, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0003-3442-4453
Mathew M YehDepartment of Pathology, University of Washington School of Medicine, Seattle, WA, USA.
Naga ChalasaniDepartment of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Cynthia D GuyDepartment of Pathology, Duke University, Durham, NC, USA.ORCID 0000-0002-4959-751X
NASH Clinical Research Network
Indiana University School of MedicineJohns Hopkins University · USCleveland Clinic · USDuke University · USNational Cancer Institute · USPacific Rim Engineering (United States) · USSaint Louis University · USUniversity of California, San Francisco · USUniversity of Washington · US

Funding

WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
QAQC Johns Hopkins Institute for Clinical and Translational ResearchUL1TR003098 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2019 to 2023
$57.7M
Northwestern University Clinical and Translational Science Institute (NUCATS)UL1TR001422 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI D'AQUILA, RICHARD · 2015 to 2023
$56.8M
Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Institute of Translational Health SciencesUL1TR000423 · NCATS · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2012 to 2016
$49.4M
Washington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4M
Clinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5M
Clinical and Translational Science Collaborative of Northern Ohio, Catalyzing Linkages to Equity in Health (CLE Health)UM1TR004528 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI GRACE A MCCOMSEY · 2023 to 2026
$32.1M
Clinical and Translational Science AwardUL1TR000040 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$26.2M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1 TR000006NCATS NIH HHS UL1 TR000040NCATS NIH HHS UL1 TR000058NCATS NIH HHS UL1 TR000077NCATS NIH HHS UL1 TR000100NCATS NIH HHS UL1 TR000150NCATS NIH HHS UL1 TR000423NCATS NIH HHS UL1 TR000424NCATS NIH HHS UL1 TR000436NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1 TR000448NCATS NIH HHS UL1 TR000454NCATS NIH HHS UL1 TR001422NCATS NIH HHS UL1 TR001442NCATS NIH HHS UL1 TR002345NCATS NIH HHS UL1 TR002548NCATS NIH HHS UL1 TR003098NCATS NIH HHS UM1 TR004528NIDDK NIH HHS U01 DK061713NIDDK NIH HHS U01 DK061718NIDDK NIH HHS U01 DK061728NIDDK NIH HHS U01 DK061730NIDDK NIH HHS U01 DK061731NIDDK NIH HHS U01 DK061732NIDDK NIH HHS U01 DK061734NIDDK NIH HHS U01 DK061737NIDDK NIH HHS U01 DK061738NIDDK NIH HHS U24 DK061730
6 · The paper itself

Abstract

BACKGROUND/

aimsGlycogen synthesis and storage are normal hepatocyte functions. However, glycogenosis, defined as excess hepatocyte glycogen visible by routine H&E light microscopy, has not been well characterized in nonalcoholic fatty liver disease (NAFLD).

methodsGlycogenosis in NAFLD liver biopsies was graded as "none", "focal" (in <50% of hepatocytes), or "diffuse" (in ≥50% of hepatocytes). Clinical and pathological variables associated with glycogenosis were assessed. 2047 liver biopsies were prospectively analysed.

resultsIn adults and children, any glycogenosis was present in 54% of cases; diffuse glycogenosis was noted in approximately 1/3 of cases. On multiple logistic regression analysis, adults with glycogenosis tended to be older (P = .003), female (P = .04), have higher serum glucose (P = .01), and use insulin (P = .02). Adults tended to have lower steatosis scores (P = .006) and lower fibrosis stages (P = .005); however, unexpectedly, they also tended to have more hepatocyte injury including ballooning (P = .003). On multiple logistic regression analysis, paediatric patients with glycogenosis were more likely to be Hispanic (P = .03), have lower body weight (P = .002), elevated triglycerides (P = .001), and a higher fasting glucose (P = .007). Paediatric patients with glycogenosis also had less steatosis (P < .001) than those without.

conclusionsGlycogenosis is common in adult and paediatric NAFLD, and is associated with clinical features of insulin resistance. Glycogenosis is important to recognize histologically because it may be misinterpreted as ballooning, and when diffuse, confusion with glycogen storage disorders or glycogenic hepatopathy must be avoided. The newly observed dichotomous relationship between glycogenosis and increased liver cell injury but decreased steatosis and fibrosis requires further study.

Indexed as

Glycogen Storage DiseaseInsulin ResistanceNon-alcoholic Fatty Liver DiseaseAdultChildFemaleFibrosisHumansLiveradultschildrenhepatic glycogenpathologysteatohepatitis

Identifiers

PMID33354866
PMCPMC8052274
OpenAlexW3116941629

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.